Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) Appoints New CMO

Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) appointed Lorianne Masuoka, MD, as CMO, effective March 2, 2015. She will replace interim CMO, Lou Vaickus, MD. Prior joining Invivo, Dr. Masuoka served as Chief Medical Officer and Senior VP at Cubist Pharmaceuticals. She was a member of executive management team and managed more than 150 employees in areas of drug safety, data management, clinical operations, biostatistics and clinical research.

The past experience

Prior to her role at Cubist, Dr. Masuoka served at various profiles of greater responsibility at Nektar Therapeutics, including Chief Medical Officer and Senior VP. She also served as VP of Clinical Development at FivePrime Therapeutics. Prior to 2003, Dr. Masuoka was associated with Chiron as Director of Clinical Department, Oncology.


Dr. Masuoka pursued her medical education at the University of California, where she also pursued her residency in neurology. She did her epilepsy fellowship from Yale University. She even received a board certificate from ‘The American Board Of Neurology.’

The management view

Mark Perrin, the CEO of Invivo said that the board is delighted to have Dr. Masuoka in Invivo team at an exciting time in company’s history. She will play an important role in transition period. She will look after all activities starting from executing the pilot study to planning of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)’s pivotal study. She has extensive experience in clinical development, looking, after all, the development in all stages of clinical trials in neurological and several multidisciplinary indications. She will prove to be an invaluable asset as the company works on its current and future clinical programs.

The other details

Perrin also said that Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) acknowledges the contribution of Vaickus in growth of Invivo. He worked with expert team to commence the first clinical trial. During his tenure, he guided collaboration with the FDA to improve the efficiency of Invivo’s first in man study.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.